Vitreomacular adhesion can lead to tractional forces on the retina (vitreomacular traction), which can lead to symptoms (most notably metamorphopsia, visual acuity and visual field defects) and ...

Which treatment you'll have for vitreomacular adhesion (VMA) depends on your symptoms. If you have none, you may not need to be treated right now. But if you’ve noticed changes to your vision ...

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole LEUVEN, Belgium, August 2, 2013 ...

Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion LEUVEN, Belgium, August 16, 2013 /PRNewswire/ -- Canada is first market outside the US ...

BLA Submitted for Ocriplasmin for Symptomatic Vitreomacular Adhesion. December 23, 2011 . ThromboGenics announced that is has submitted a Biologics License Application (BLA) to the FDA ...

Today's kick off in Germany's private and public market, follows Alcon's first European launch of JETREA ® which took place in the UK last month. Alcon, a division of Novartis, acquired the ...

ThromboGenics has received FDA approval for a drug to treat symptomatic vitreomacular adhesion, according to a news release. The drug, Jetrea, is approved to treat the eye condition, which can ...

Wednesday, December 25, 2024. News & Perspective Drugs & Diseases CME & Education Drugs & Diseases CME & Education ...

ThromboGenics has received FDA approval for a drug to treat symptomatic vitreomacular adhesion, according to a news release. The drug, Jetrea, is approved to treat the eye condition, which can ...